Brendan M. Giles, PhD

Postdoctoral Fellow

Dr. Brendan Giles



PhD in Immunology, University of Pittsburgh, School of Medicine, 2011

BS in Biology, Loyola University Chicago, 2002




Ted M. Ross, PhD


Areas of Interest

Vaccine design and development, Immunology of infectious disease

Why I Chose Pitt

The University of Pittsburgh provided a unique opportunity to investigate immunology of infectious disease using emerging pathogens. Developing vaccines for highly pathogenic viruses is exciting and translates directly to improving human health. The outstanding faculty and state-of-the-art facilities combine to create an environment that fosters independent thought and collaboration, which have been essential to my growth as a scientist.

Following his graduation from the University of Pittsburgh, Brendan accepted a position as a Postdoctoral Fellow at the University of Colorado in the Department of Rheumatology.

Book Chapters

Ross TM, Bhardwaj N, Eugene HS, Giles BM, McBurney SP, Rossi SL, Schneider-Ohrum K, Tang X. "Virus Like-Particle Vaccines: Advantages and Challenges" Development of Vaccines: From Discover to Clinical Testing. 2009. Wiley and Sons (USA)


Giles BM, Bissel SJ, Wiley CA, Ross TM. 2011. Computationally Optimized Broadly Reactive Antigen (COBRA): A novel strategy for developing a broadly reactive vaccine against H5N1 influenza.  Vaccines Against Emerging Infectious Diseases. Montego Bay, Jamaica. Oral Presentation.

Giles BM, Ross TM. 2010. Elicitation of broadly reactive immune responses using a consensus H5N1 virus-like particle. American Society for Virology: 29th Annual Meeting. Bozeman, MT. Oral presentation.

Giles BM, Tumpey TM, Ross TM. 2010. Elicitation of Protective Immune Responses to Swine Origin H1N1 Using a 1918 Virus-Like Particle. Swine Origin H1N1 Virus: The First Pandemic of the 21st Century. Atlanta, GA. Poster Session.

Giles BM, Crevar CJ, Tumpey TM, Ross TM. 2009. Elicitation of protective immune responses using a 1918 influenza virus-like particle. 7th Biodefense and Emerging Diseases Research Meeting. Baltimore, MD.  Oral presentation.



A Computationally-Optimized Hemagglutinin VLP Vaccine Elicits Broadly-Reactive Antibodies that Protect Monkeys from H5N1 Infection. J Infect. Dis. [Under review] |  

Elicitation of anti-1918 influenza immunity early in life prevents morbidity and lower lung infection by 2009 pandemic H1N1 influenza in aged mice. J Virol. [In revision] |  

Acute Murine H5N1 Influenza A Encephalitis. Brain Pathol. [In press] |  

Schneider-Ohrum, K; Giles, B. M; Weirback, H. K; Williams, B. L; DeAlmeida, D. R; and Ross, T. M. (2011) Adjuvants that Stimulate TLR3 or NLPR3 Pathways Enhance the Efficiency of Influenza Virus-like Particle Vaccines in Aged Mice. Vaccine. 29: 9081-9092. |  View Abstract

Acute Murine H5N1 Influenza A Encephalitis. Brain Pathol. [Epub ahead of print] |  View Abstract

Giles, B. M; and Ross, T. M. (2011) A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine. 29: 3043-3054. |  View Abstract

Seroprevalence following the second wave of Pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA. PLoS One. 5: e11601. |  View Abstract

Synovial Fluid Proteins Differentiate Between the Subtypes of Juvenile Idiopathic Arthritis. Arth & Rheum. 62: 1813-1823. |